Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 34OTHER 17NIH 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 6Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Urinary Bladder Neoplasms 2Nasopharyngeal Carcinoma 2Hodgkin Disease 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Renal Insufficiency 1Neoplastic Cells, Circulating 1Locally Advanced Cervical Cancer 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Carcinoma, Transitional Cell 1

Interventions

camrelizumab 2Injections 2toripalimab 1epigallocatechin gallate 1atezolizumab 1Zinc 1Tablets 1Quercetin 1Nivolumab 1Metformin 1Imatinib Mesylate 1Gemcitabine 1Everolimus 1Epirubicin 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Triple Negative Breast Neoplasms × Gemcitabine × Clear all
NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

National Cancer Center, Korea

Phase 1/2 Terminated
23 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡